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1 GENERAL PART 
 
1.1 Introduction 
 
In analytical toxicology, a broad range of compounds have to be detected and 
identified in case of intoxications and poisonings [1]. The presence or absence of 
drugs, drugs of abuse, poisons, and/or their metabolites must be confirmed by 
unequivocal toxicological analyses [2]. As in most cases the administered drug or 
poison is not known, a so-called general unknown screening (GUS) is one of the 
major tasks in clinical and forensic toxicology, workplace drug testing, and doping 
control. Urine screening offered best prerequisites as drugs are excreted, more or 
less metabolized, in higher concentrations over a longer period of time in urine after 
concentration in the kidney compared to blood plasma [3]. Detection of metabolites 
provided several advantages. It allowed monitoring of drugs, which are excreted in 
completely metabolized form, and confirmed the body passage and thus the intake of 
a drug [2,4]. Furthermore, detection of various metabolites helps to confirm the taken 
drug and lowers the risk of false negative results if the ionization of the drug or one 
metabolite is completely suppressed e.g. by matrix [5]. Despite shorter detection 
windows, blood (plasma, serum) can be essential if urine cannot be provided 
because of e.g. drug-induced urinary retention or acute renal failure [3]. 
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1.2  Screening Procedures 
 
Immunoassays can be used for preliminary screening of a single drug or drug class 
[3]. Due to interferences with other drugs or biomolecules resulting in false-positive 
results, they should be confirmed by a second independent method [6]. Therefore, 
mass spectrometry (MS) was established in the field of clinical and forensic 
toxicology providing higher identification power, sensitivity and specificity [6]. 
Application of hyphenated mass spectrometric techniques such as gas 
chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass 
spectrometry (LC-MS) in this field has been reviewed elsewhere [3,6]. In recent 
years, high resolution (HR) mass spectrometry, already established in proteomics, 
was introduced also in bioanalysis of small molecules [2,7-9].  
 
1.2.1 Sample Workup 
 
Sample workup procedures for GUS should be universal in order to assure 
reproducible recovery of a broad range of compounds with different physicochemical 
properties [10]. Apart from laborious workup approaches such as liquid-liquid 
extraction [11,12] or solid-phase extraction (SPE) [13,14], fast and simple dilute-and 
shoot approaches [15-17] and precipitation were used for comprehensive screening 
procedures [5]. Stahnke et al. described for the analysis of pesticides that a 25-40 
fold dilution of samples could reduce the ion suppression to less than 20% [18]. 
Dilution or precipitation of a sample might result in reduced detectability [17]. 
Evaporation of the dilution/precipitation solvent might increase sensitivity by 
concentration as described by Wissenbach et al. [5,19], but could result in higher 
matrix effects [20]. 
Due to the high sensitivity of time-of-flight (TOF) and orbitrap (OT) mass 
spectrometers, simple and fast sample workup approaches should be feasible. 
Online SPE [21-24], micro-extraction [22,23], and on-line extraction by turbulent flow 
chromatography (TurboFlow) [23,25,26] represented fast and automated sample 
workup approaches. TurboFlow was first introduced in the late 1990s for online 
sampling in bioanalysis [26]. It was based on the principle of size exclusion 
chromatography to separate macromolecules such as proteins from smaller 
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molecules in complex biological fluids, such as blood plasma or urine [26]. The basis 
for this methodology was “turbulent flow” with flow rates above 1.2 mL/min using 0.5 
mm I.D. columns packed with large particles of 30 – 50 µM resulting in low 
backpressures [25]. However, direct injection of undiluted biological samples might 
cause carry-over and autosampler blockage [26]. In order to prevent this, prior 
precipitation was still recommended to maximize column life. Most TurboFlow 
methods were applied for narrow target screening of e.g. beta-agonists, drugs of 
abuse, or the mushroom poisons α- and β-amanitin [27-29]. Recently, a new 
TurboFlow mode, the so-called pseudo quick elute mode, was developed for reliable 
detection of α- and β-amanitin as well as for fully validated quantification of  
α-amanitin [29]. It offered more options for method optimization and showed better 
practicability in routine and emergency analysis compared to previous methods. 
Mueller et al. developed the first screening approach for over 300 parent compounds 
and major phase I metabolites in urine after manual hydrolysis using TurboFlow [30]. 
 
1.2.2 Chromatography and Mass Spectrometry 
 
1.2.2.1 Gas and Liquid Chromatography - Low Resolution Mass Spectrometry 
 
GC-MS with its high separation power of GC and high selectivity of electron 
ionization MS in combination with comprehensive electron impact spectra based 
reference libraries and sophisticated search algorithms provided outstanding non-
targeted screening results [3,10,31,32]. However, it required derivatization and the 
technique was limited to volatile and thermostable analytes. 
LC-MS overcomes those disadvantages, thus several LC-MS, LC-MS/MS, or LC-MSn 
screening procedures using library search were developed and reviewed elsewhere 
[2,10]. Different mass analyzers such as triple quadrupoles [33], ion traps 
[5,19,21,30], and hybrids of both techniques [34] were used. Wissenbach et al. [5,19] 
developed the first metabolite-based LC-MSn urine drug screening procedure using 
data-dependent acquisition (DDA) and MS2 and MS3 reference spectra. The library 
consisted of data of more than 1,500 drugs and about 3,000 metabolites (including 
phase II metabolites) or artifacts recorded from reference standard solutions and 
authentic rat or human urine samples after administration or consumption of the 
corresponding drugs [35].  
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1.2.2.2 Liquid Chromatography-High Resolution Mass Spectrometry 
 
Background 
Instruments with increased high mass resolving power made it possible to calculate 
empirical formula of chemical compounds from accurate mass measurements 
[35,36]. The combined atomic masses (based on the most abundant isotope of each 
atom) of the empirical formula of an ion or molecule, for example 12.000000 + 
4(1.007825) = 16.0313 Da for CH4, allowed calculation of the exact molecular mass 
[36]. Already in early time of GC-MS, HRMS using double-focusing sector field mass 
analyzers were used for GUS in order to determine the accurate mass and the 
corresponding empirical formula of unknown compounds in blood or urine [2,37].  
The principles of TOF- and OT-MS measuring exact masses were reviewed 
elsewhere in detail [36,38]. The principle of an OT-MS will shortly be explained here. 
In a multiple collision cell, higher-energy collisional dissociation (HCD) takes place 
[39]. Ions are trapped then radially about a central spindle electrode. Mass/charge 
values are measured from the frequency of harmonic ion oscillations along the axis of 
the electric field [39]. Ion frequencies are measured by acquisition of time-domain 
image current transients. Afterwards fast Fourier transforms are used for conversion 
to HR mass spectra. HR mass spectrometers provide several advantages such as 
high selectivity, sensitivity, and specificity in combination with the option to predict 
empirical formula of molecules or fragments formed during ionization due to accurate 
mass measurements [9].  
Thus, they provide best prerequisites for its application for broad screening and 
library-assisted identification of drugs, poisons, and their metabolites. LC-HRMS 
screening procedures have been reviewed elsewhere in detail [9,40]. In the following, 
the application of HRMS for GUS will be described for TOF, sequential window 
acquisition of all theoretical fragment ion spectra (SWATH) technology, and then be 
focused on OT technology and adherence testing in cardiology. 
 
Time-of-Flight-based Screening Procedures 
For comprehensive screening by HRMS, mainly TOF analyzers were applied 
[11,13,41-43]. First approaches were based on accurate mass lists [44,45]. Polettini 
et al. [44] worked with an accurate mass list of over 50,000 compounds including 
metabolites taken from the PubChem Compound database. Comparing measured 
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accurate masses with lists of theoretical accurate masses (exact masses) provided 
only preliminary screening results. An important disadvantage of compound 
identification only by accurate mass is that there are several isomeric compounds, 
which cannot be differentiated by this approach and a following confirmation step is 
required. Liotta et al. [45] tried to improve isomer identification with a metabolomics 
approach by checking if isomeric compounds undergo major metabolic reactions. In 
the following, DDA based screening approaches with different identification criteria 
will be described. Compound identification by Lee et al. [11] was based on exact 
mass, retention time, nominal mass spectra followed by empirical formula analysis, 
and examination of the isotopic patterns. However, using two voltages for spectra 
recording increased the cycle time. De Castro et al. [13] described identification 
based on accurate mass, relative retention time, and collision induced dissociation 
(CID) spectra comparison with up to three qualifier ions. Broecker et al. [12] 
developed a screening approach for 2,500 compounds based on full scan (FS) and 
HR product ion spectra using a TOF instrument with a quadrupole in front (Q-TOF) in 
DDA mode with CID spectra recorded at three collision energies of 10, 30, 40 eV. 
DDA is the more established technique and has been successfully used for low-
resolution (LR) [5,30], but also for HR instruments as described by Broecker et al. 
[12]. The precursor ions were identified in FS and then considered for MS/MS 
experiments [46]. The main criterion is signal intensity, only most abundant ions 
exceeding an intensity threshold are chosen for fragmentation experiments. In order 
to prevent generation of too many spectra per time frame and mixed spectra, only a 
limited number of possible precursor ions is introduced to MS/MS experiments. 
Therefore, dynamic exclusion and background subtraction were developed for DDA 
mode [47].  
Besides, TOF screening procedures based on data-independent acquisition (DIA) 
were developed. Sundstrom et al. [42] developed an ultra-high-performance-liquid 
chromatography (UHPLC) HR-TOF-MS procedure for designer drugs and drugs of 
abuse in urine using all-ion fragmentation with a database of 277 compounds. 
Identification was based on accurate masses, retention time, and isotopic patterns 
and up to two fragment ions (FIs) as qualifier ions. Chindarkar et al. [48] presented a 
broad-spectrum UPLC-TOF-MS screening method for urine after dilution and 
enzymatic cleavage of conjugates with the identification criteria accurate mass 
precursor ion, retention time, and one FI match. They reported that certain drug 
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classes required high-energy collisions with the disadvantage of forming many low 
abundant FIs. Kinyua et al. [49] presented a qualitative screening procedure based 
on all-ion fragmentation mode on a Q-TOF-MS for new psychoactive substances and 
their metabolites with identification criteria accurate mass precursor ion and manual 
evaluation of FIs. Thoren et al. [50] compared the performance of a broad-spectrum 
Q-TOF unknown screening with a linear ion trap targeted drug screening, which were 
both operated in DDA mode. Q-TOF offered similar identification power compared to 
the linear ion trap.  
In the described DDA and DIA based screening approaches different identification 
criteria such as accurate mass precursor ions and spectra comparison were 
described. However, spectra generation at two different conditions could increase 
cycle times and applying too high fragmentation energies might result in too many 
low abundant FIs. In addition, the lack of suitable software solutions for TOF data 
evaluation required manual data evaluation in some cases. In comparison to OT 
technology, TOF-MS provided higher acquisition frequencies and typically required 
internal calibration to correct the mass axis [51], which might provide some 
disadvantages such as interference with the ionization process of the sample. 
Nevertheless, comprehensive Q-TOF screening approaches could be an alternative 
for untargeted urine drug screening. 
 
Sequential Window Acquisition of All Theoretical Fragment Ion Spectra based 
Screening Procedures  
As already discussed by Maurer and Meyer [9], SWATH provides a promising 
alternative option for non-targeted HRMS Q-TOF screening in clinical and forensic 
toxicology. It is a DIA technique, where ions are allowed to pass quadrupole one in a 
defined medium window size of 20 or 25 Da across the scan range of interest [52,53]. 
Ions in each of those windows are transferred into the collision cell and product ions 
are generated under high collision energy. The product ions are then sequentially 
analyzed by the HR-TOF analyzer. In the following, different SWATH-based methods 
will be described. 
Arnhard et al. [54] used SWATH in combination with Q-TOF for acquisition of HR-
MS/MS spectra after precursor ion selection in 21 Da isolation windows. They 
showed that SWATH is a more sensitive and specific identification tool for 
compounds at lower concentration levels compared to DDA. But only semi-
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automated data evaluation was possible confirming data processing to be a laborious 
and time-consuming process. Roemmelt et al. [55] investigated isolation windows of 
20-35 Da for its suitability for systematic toxicological analysis. Although relative 
abundance of the fragments was concentration-dependent and influenced by co-
fragmentation, SWATH detection rate was better than DDA, which failed to trigger 
about 10% of the analytes. 
In theory, DIA allowed generation of mass spectral information for all precursor ions 
[46]. As described above, SWATH showed more identification power, sensitivity, and 
specificity compared to DDA. However, if multiple compounds were dissociated in 
one experiment, mixed spectra resulted and had to be interpreted. Sufficient 
deconvolution algorithms would be necessary for those screening procedures, but 
only semi-automated data evaluation was described yet. 
 
Orbitrap-based Screening Procedures 
As already discussed by Maurer and Meyer [9], only few OT-based methods were 
published up to now for comprehensive screening of drugs of abuse and 
pharmaceuticals in clinical and forensic toxicology. 
Li et al. [56] developed a screening procedure for 65 drugs of abuse such as 
cannabinoids in human urine by using an LTQ-OT-MS. However, they used time 
consuming SPE and had to perform separate runs in positive and negative ionization 
mode due to slow switching times of the instrument. Identification was based on 
accurate mass, retention time, and exact masses of the FIs using ToxID software. 
Roche et al. [57] described a GUS procedure with a library of 616 mainly parent 
compounds in serum, urine, and whole blood samples after TurboFlow. The OT-MS 
was operated in positive and negative ionization mode with subsequent HCD 
fragmentation. Identification criteria were accurate masses, retention time, isotopic 
patterns, and the presence of specific FIs. Montesano et al. [58] developed a broad 
screening for new psychoactive substances on an OT with quadrupole precursor 
selection (Q-OT) instrument including cathinones and synthetic cannabinoids in blood 
plasma. They performed a FS for targeted screening with subsequent all ion 
fragmentation considering two specific product ions for data analysis of over 300 
compounds by automated TraceFinder data evaluation software. 
Novel Q-OT mass spectrometers offered long-term stability of external mass 
calibration, unique high resolving power, sub ppm mass accuracies over a wider 
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dynamic range compared to TOF instruments [51,59]. In contrast to TOF-based 
screening procedures, first automated data evaluation software packages were 
described. Therefore, Q-OT mass spectrometers should be appropriate for 
comprehensive toxicological screening of various drug classes and their metabolites 
[2]. 
 
Adherence Testing in Cardiology 
Nonadherence of the patients to a prescribed drug therapy could be one reason for 
treatment-resistant hypertension. This is indicated by blood pressure levels > 140/90 
mm Hg when three or more antihypertensive drugs of different classes including a 
diuretic were taken at maximal tolerated dose [60]. In hypertensive patients its 
prevalence ranges from 5 - 30% and is connected to an increased risk of 
cardiovascular and renal events [60-62]. Jung et al. [63] presented the first study on 
a targeted urine drug screening for patients with apparent resistant hypertension. 
Based on these screening results they confirmed adherence of patients and showed 
the utility of this approach. In the field of metabolomics, van der Hooft et al. [64] 
developed a urinary antihypertensive drug metabolite screening making use of 
molecular networking coupled to HRMS fragmentation. Their method offered 
possibilities for untargeted identification of drugs and their metabolites. 
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2 AIMS AND SCOPES  
 
The aim of this dissertation was to develop a comprehensive, metabolite-based, 
automated LC-HR-MS/MS screening procedure by OT technology for drugs, poisons, 
and their metabolites, being relevant to clinical and forensic toxicology. As a 
complement to already existing GC- and LC-MSn libraries [32,35], high resolution 
MS/MS spectra of drugs should be collected of reference standards in methanolic 
solution. Those of metabolites should be identified in urine samples of rats or humans 
after corresponding drug administration and in incubates of drugs with pooled human 
liver preparations.  
 
The following should be conducted: 
 Development of simple sample workup procedures and comparison with 
established ones 
 Development of fast und sufficient universal UHPLC separation 
 Development of a new HRMS detection method by Q-OT including study of 
conditions for mass spectra recording and reproducibility 
 Validation of the method for a selection of drugs of various drug classes 
according to recommendations for qualitative methods [65,66] after different 
sample workups of urine and blood plasma 
 HR-MS/MS drug spectra collection by using the above-mentioned reference 
standard solutions 
 Identification of metabolites of drugs and poisons in urine or incubates of liver 
preparations by detailed HR MS/MS spectra and implementation of those into 
the new HRMS reference library 
 Establishment of new, automated HR-MS/MS data evaluation with different 
detection and identification criteria 
 Application of the screening method to particular drug classes  
 Studies on the application of HRMS for blood plasma screening 
 Evaluation of HRMS for differentiation of isobaric and isomeric compounds, 
and for GUS 
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3 PUBLICATIONS OF THE RESULTS 
 
The results of the studies were published in the following papers: 
 
3.1 Orbitrap technology for comprehensive metabolite-
based liquid chromatographic-high resolution-tandem 
mass spectrometric urine drug screening - exemplified 
for cardiovascular drugs [67] 
(DOI:10.1016/j.aca.2015.08.018) 
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3.2 LC-HR-MS/MS standard urine screening approach: Pros 
and cons of automated on-line extraction by turbulent 
flow chromatography versus dilute-and-shoot and 
comparison with established urine precipitation [68] 
(DOI: 10.1016/j.jchromb.2016.06.036) 
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3.3 Liquid chromatography-high resolution-tandem mass 
spectrometry using Orbitrap technology for 
comprehensive screening to detect drugs and their 
metabolites in blood plasma [69] 
(DOI: 10.1016/j.aca.2017.03.002) 
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4 DISCUSSION AND CONCLUSIONS  
 
In the first part of this thesis, OT technology was successfully applied for 
development of a comprehensive metabolite-based LC-HR-MS/MS screening 
approach for urinalysis of drugs relevant in clinical and forensic toxicology [67]. 
Different new urine sample workup procedures using on-line extraction by TurboFlow 
and a dilute-and-shoot approach were developed and compared with already 
established urine precipitation [68]. The “pseudo quick elute mode” for TurboFlow, 
which has already been described for the analysis of amanitin [29], offered some 
advantages for urine drug screening such as less manual handling compared to 
precipitation. Only if a higher number of samples have to be analyzed per day, the 
reduction of total analysis time outweighed the limitations of TurboFlow such as 
additional costs for equipment, columns and maintenance. A broad range of drugs 
with different physicochemical properties could be detected and identified after 
common dosages after all sample workups with better identification limits for 
precipitation and TurboFlow. However, only some low-concentrated drugs and 
metabolites might not be identified after simple dilution. The screening approach was 
also suitable for qualitative blood plasma screening [69]. Due to lower drug 
concentrations in blood plasma and fewer metabolites compared to urine, targeted 
blood plasma screening with preferred MS/MS spectra acquisition was performed on 
700 compounds and main metabolites in blood plasma. This was followed by DDA 
mode for identification of unknowns. Final identification criteria were the presence of 
accurate mass precursor ions, five most intense FIs, and HR-MS/MS library match. 
High amounts of both parent drugs and metabolites, covered by urine screening, in 
combination with blood plasma screening will ensure definite identification of 
compounds. The procedure was successfully applied for cardiovascular drugs to 
assess medication adherence of hypertension patients [70-72]. Thus, in the context 
of adherence testing, Linicus et al. [70] were able to demonstrate the relevance of 
excluding non-adherence to prescribed drugs by adherence screening before renal 
denervation. Ewen et al. [71,72] showed the usefulness of renal denervation to 
reduce blood pressure in patients with resistant hypertension and reported the 
corresponding mechanisms.  
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As mentioned above, HR-FS in combination with DDA mode allowed detection and 
identification of unknown drugs, their artifacts, and metabolites. Thus, new drugs 
appearing on the market such as novel psychoactive substances, which were neither 
added to the inclusion list nor to the current reference library, can be detected. 
Accurate mass measurement allows proposing the empirical formula of the precursor 
ion of the new compound and/or its metabolites. The combination with accurate 
masses/empirical formulas of the formed MS/MS fragments may help in identifying 
the compound. This was e.g. shown for elucidation of phase I and II metabolism of 
the novel psychoactive substance 4-methyl-N-ethcathinone by Helfer et al. [73]. In 
this case, isobaric compounds could be differentiated by HR-FS due to accurate 
mass measurements. As an example, Maurer and Meyer [9] described differentiation 
of the new psychoactive substances beta-keto-2CB ((2-amino-1-(4-bromo-2,5-
dimethoxyphenyl)ethanone) and DOB (2,5-dimethoxy-4-bromamphetamine) showing 
in addition to the precursor ion three identical nominal mass FIs [74]. LC-HR-MS/MS 
allowed differentiation of the corresponding precursor ions and FIs by their accurate 
masses.  
However, isomeric compounds cannot be differentiated in full scan mode by HR-MS, 
but by different fragmentation and/or chromatographic separation. The risk of 
overlooking co-eluting isomeric compounds due to common precursors and/or risk of 
complete ion suppression by the matrix could be minimized by inclusion of 
metabolites and by recording spectra in negative ionization mode. Some compounds 
showed better negative ionization properties, but some drugs such as thiazide 
diuretics were exclusively detected in this ionization mode due to their chemical 
structure.  
Initial studies showed that HCD fragmentation at three collision energies provided a 
mixed spectrum with formation of enough FIs. However, less than five FIs could not 
be sufficient for differentiation of isomeric compounds based on different fragments. 
Due to a different search algorithm of the data evaluation software for FI matching 
compared to full HR-MS/MS library matching, FIs provided additional identification 
certainty. Isotopic patterns were no longer taken into account for final data evaluation 
because they were not completely detected although the most abundant isotope 
(accurate mass precursor ion) provided an MS/MS spectrum. Those findings 
confirmed that full HR-MS/MS library spectra provided highest identification power 
according to the European Commission Decision 2002/657/EC [75]. In cases of 
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doubt, retention times of the compounds can be considered. Despite the advantages 
of HRMS for GUS, the technique still showed some limitations [9]. The HR mass 
spectrometers are comparably expensive, require intensive maintenance, and the 
huge size of recorded data affords solutions regarding data storage and evaluation. 
Evaluating unknown HR data is laborious, time-consuming, and considerable mass 
spectrometry skills are required. In the author´s opinion, LR mass spectrometers fulfill 
the criteria for comprehensive drug screening at low purchase costs and acceptable 
identification power. However, high selectivity and identification power by HRMS can 
be mandatory for differentiation of isobaric compounds, co-eluting isomeric 
compounds, and tentative identification of unknown drugs and/or metabolites. Further 
studies investigating the transferability of the HR-MS/MS library to other HR 
instruments and the influence of different instrument types and settings on the quality 
of screening results are necessary.   
  
- 20 - 
 
5 SUMMARY 
 
In the presented thesis, development of an automated and comprehensive 
metabolite-based LC-HR-MS/MS screening procedure using OT technology for 
detection of drugs and poisons relevant in clinical and forensic toxicology is 
described. Therefore, new urine sample workup procedures based on automated on-
line extraction by TurboFlow and simple dilution were developed and compared with 
established urine precipitation. After universal UHPLC separation, drugs and 
metabolites were detected and identified by an OT mass spectrometer operated in 
FS mode with positive/negative switching and subsequent DDA mode. Based on 
these conditions, a new mass spectral reference library with over 5,000 HR-MS/MS 
spectra containing about 2,000 parent compounds and 3,000 metabolites was 
developed. The screening approach was successfully applied to blood plasma. A 
new automated HR-MS/MS data evaluation considering accurate mass precursor 
ions, five most intense FIs, and full HR-MS/MS library spectra was established. The 
new LC-HR-MS/MS screening approach complements the existing GC-MS and LC-
MSn screening procedures and is the basis for metabolism studies of various drug 
classes. It is successfully applied in daily routine analysis for GUS and adherence 
testing of hypertension patients. Analysis of thousands of patient samples showed 
robustness, selectivity, sensitivity, and specificity of the method.  
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7 ABBREVIATIONS 
 
CID    collision-induced dissociation 
DDA    data-dependent acquisition 
DIA    data-independent acquisition 
FI    fragment ion 
FS   full scan 
GC    gas chromatography 
GUS   general unknown screening 
HCD    higher-energy collisional dissociation 
HR   high resolution 
LC    liquid chromatography 
LR    low-resolution 
MS    mass spectrometry  
OT   orbitrap 
SPE   solid-phase extraction  
SWATH  sequential window acquisition of all theoretical fragment ion 
spectra 
TOF    time-of-flight 
TurboFlow   turbulent flow chromatography 
UHPLC   ultra-high-performance-liquid chromatography 
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8 ZUSAMMENFASSUNG 
 
Im Rahmen dieser Dissertation wird die Entwicklung eines automatisierten und 
umfangreichen, Metaboliten-basierten Screeningverfahrens mittels LC-HR-MS/MS-
Technik unter Verwendung der Orbitrap-Technologie zum Nachweis von in der klini-
schen und forensischen Toxikologie relevanten Arznei- und Giftstoffen beschrieben. 
Hierzu wurden neuartige Probenaufarbeitungsverfahren für Urin basierend auf auto-
matisierter Turbulent Flow On-line Extraktion und einfacher Verdünnung entwickelt 
und mit der bereits etablierten Proteinfällung verglichen. Unter Verwendung einer 
universellen UHPLC Trennung wurden die Muttersubstanzen und Metaboliten detek-
tiert und identifiziert mittels eines Orbitrap Massenspektrometer, das im Full-Scan-
Modus abwechselnd positiv oder negativ ionisierte Analyten erfasste und anschlie-
ßend im datenabhängigen Erfassungsmodus betrieben wurde. Unter Anwendung 
dieser Bedingungen entstand eine neue Referenzspektrenbibliothek mit inzwischen 
über 5.000 hochaufgelösten Massenspektren, die rund 2.000 Muttersubstanzen und 
3,000 Metaboliten umfasst. Das Verfahren wurde erfolgreich auf das Screening im 
Blutplasma übertragen. Eine neue automatisierte Auswertung, die die akkuraten 
Massen der Vorläuferionen, die der fünf intensivsten Fragmentionen und die 
vollständigen, hochaufgelösten MS/MS Bibliotheksspektren berücksichtigt, wurde 
etabliert. Das neue LC-HR-MS/MS Screeningverfahren ergänzt die bestehenden  
GC-MS und LC-MSn Screeningverfahren und ist die Grundlage zur Aufklärung des 
Metabolismus von verschiedensten Subtanzklassen. Es wird erfolgreich in der 
täglichen Routineanalytik zum allgemeinen Screening auf unbekannte Substanzen 
und zur Überprüfung der Adhärenz von Bluthochdruckpatienten eingesetzt. Die 
Analyse tausender Patientenproben zeigte die Robustheit, Selektivität, Sensitivität 
und Spezifizität der Methode. 
 
